CytomX Therapeutics and ImmunoGen to Develop Probody-Drug Conjugates - - BioPharm International

ADVERTISEMENT

CytomX Therapeutics and ImmunoGen to Develop Probody-Drug Conjugates


CytomX Therapeutics, a probody therapeutics company, and ImmunoGen, a biotechnology company that develops targeted anticancer therapies using its antibody-drug conjugate (ADC) technology, have entered into a collaboration to develop probody-drug conjugate (PDC) therapies for the treatment of cancer.
Under the terms of the agreement, the companies will collaborate to develop PDCs against a defined number of targets. This collaboration brings together CytomX’s proprietary antibody masking technology and tumor-selective protease substrates with ImmunoGen’s ADC cell-killing agents and engineered linkers.

According to a press statement, each company retains full development control of PDC compounds resulting from its target selection and is responsible for preclinical and clinical testing, manufacturing, and commercialization. Each company is entitled to potentially receive clinical and post-approval milestone payments from the other company, as well as royalties on the sales of any marketed products resulting from this collaboration.  

Source: CytomX Therapeutics

 

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Novartis Reports Positive Results for Secukinumab in Ankylosing Spondylitis Trials
October 23, 2014
Pall ForteBio Releases Bioprocessing Contamination Detection Kit
October 22, 2014
Roche to Expand and Improve its Basel Site
October 22, 2014
FDA Panel Unanimously Backs Secukinumab for the Treatment of Psoriasis
October 22, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Author Guidelines

Click here